Nutritional status according to the mini nutritional assessment (MNA)® as potential prognostic factor for health and treatment outcomes in patients with cancer – a systematic review

Torbahn, G.; Strauss, T.; Sieber, C. C.; Kiesswetter, E.; Volkert, D.

doi:10.1186/s12885-020-07052-4

Table 1 Study and patient characteristics of included studies

From: Nutritional status according to the mini nutritional assessment (MNA)® as potential prognostic factor for health and treatment outcomes in patients with cancer – a systematic review

Author/ Year	Country	N^a	Age (years)^b	Female (%)	Type of cancer	Cancer stage (early/ mixed/ advanced)	Anticancer therapy	MNA-form	MNA-result^c			Outcome
Author/ Year	Country	N^a	Age (years)^b	Female (%)	Type of cancer	Cancer stage (early/ mixed/ advanced)	Anticancer therapy	MNA-form	MN (%)	AR (%)	WN (%)	Outcome
Aaldriks 2011	NL	202	77 ± 4	55	Various	Mixed	Chemo	SF/LF^d	2.5	29.7	64.9	Mortality^e Treatment maintenance
Aaldriks 2013a	NL	143	75 (70–92)	41	Colorectal	Mixed	Chemo	SF/LF^d	28.0		72.0	Mortality Treatment maintenance
Aaldriks 2013b	NL	55	76 ± 5	96	Breast	Advanced	Chemo	SF/LF^d	41.8		54.5	Mortality Treatment maintenance
Aaldriks 2015	NL	44	78 (70–86)	57	Various	Mixed	Chemo	SF/LF^d	34.1		65.9	Mortality Treatment maintenance
Aaldriks 2016	NL	494	75 (70–92)	51	Various	Mixed	Chemo	SF/LF^d	35.2		64.0	Mortality Treatment maintenance
Allaire 2017	Canada	144	69 ± 10	22	Bladder	Mixed	Surgery	SF	9.0	43.0	48.0	Complications
Aparicio 2018	France	102	81 (75–89)	45	Colorectal	Advanced	Chemo	SF	66.7		33.3	Mortality PFS
Araujo 2017	Brazil	52	53 (24–85)^f	71	Various	Mixed	Chemo	LF	23.5 ± 4.2^g			Fatigue
Baier 2016	Germany	195	75 (70–88)	31	Various	n.r.	Surgery	n.r.	n.r.	56.7^h	n.r.	Functional status
Boulahssass 2018	France	1050	82 (70–100)	60	Various	Mixed	Various	LF	21.0	47.7	28.5	Mortality
D’Almeida 2020	Brazil	3061	73 ± 7	44	Various	Mixed	Various	SF	33.4	39.3	27.3	Length of hospital stay
Decoster 2016	Belgium	193	77 (70–89)	38	Colorectal	Mixed	Various	LF	56.0		44.0	Functional decline Toxicity
Decoster 2018	Belgium	252	77 (69–91)	39	Colorectal	Advanced	Various	LF	54.2		45.8	PFS Treatment duration
Decoster 2019	Belgium	2972	79 ± 6	57	Various	Mixed	Various	SF	79.1		21.9	Quality of Life
Dubruille 2015	Belgium	90	74 (65–89)	43	Hematological	Mixed	Chemo	LF	44.0		56.0	Mortality
Extermann 2012	US	n.a.ⁱ	76 (70–92)	50	Various	Mixed	Chemo	LF	25 (8–30)^g			Toxicity
Frasca 2018	France	1264	78 ± 5	70	Various	Mixed	Various	LF	41.5		58.5	Mortality
Ghosn 2017	France	100	76 (4)^j	47	Various	n.r.	Various	SF	n.r.	n.r.	n.r.	Mortality
Giannotti 2019	Italy	99	80 ± 6	38	Colorectal	Mixed	Surgery	LF	23.12 ± 3.31^g			Mortality
Giannousi 2012	Greece	122	66 (37–81)	16	Lung	Advanced	Systemic	LF	9.0	60.7	30.3	Mortality
Gioulbasanis 2011a	Greece	173	65 ± 11	17	Lung	Advanced	Various	LF	26.0	46.2	27.8	Mortality TTP
Gioulbasanis 2011b	Greece	115	66 (32–86)	12	Lung	Advanced	Chemo	LF	25.2	51.3	23.5	Mortality
Gioulbasanis 2012	Greece	114	68 ± 5	11	Lung	Advanced	Systemic	LF	29.8	41.2	29.0	Mortality TTP
Gioulbasanis 2015	France, Greece	594	69 ± 10	27	Various	Advanced	Systemic	LF	12.8	49.5	37.7	Mortality
Goineau 2018	France	100	78 (75–89)	0	Prostate	Advanced	Radio	LF	2.0	98.0		Quality of Life
Gu 2015	China	300	56 ± 12	33	Renal cell	Advanced	n.r.	SF	4.0	17.3	78.7	Mortality Toxicity
Honecker 2018	Germany	160	78	0	Prostate	n.r.	Various	SF	61.6		38.4	Treatment maintenance
Hoppe 2013	France	299	77 (70–93)	41	Various	Advanced	Chemo	LF	63.2		36.8	Functional decline
Kaibori 2016	Japan	71	78 ± 5	27	Hepatocellular	n.r.	Surgery	SF	43.7		56.3	Complications
Kenig 2015	Poland	75	73 ± 6	44	Various	Various	Surgery	LF	48.0		52.0	Complications
Kenis 2017	Belgium	439	75 (70–95)	58	Various	Mixed	Various	SF	21.4	46.9	31.7	Mortality Functional decline
Kenis 2018	Belgium	Cohort A: 763	Cohort A: 76 (70–95)	Cohort A: 68	Various	Mixed	Various	SF	Cohort A: 62.3		Cohort A: 37.7	Mortality
Kenis 2018	Belgium	Cohort B: 402	Cohort B: 77 (70–95)	Cohort B: 67	Various	Mixed	Various	SF	Cohort B: 56.5		Cohort B: 43.5	Mortality
Kim 2014	Korea	98	n.a.^k	31	Various	Mixed	Chemo	LF	20.4	47.0	30.6	Treatment maintenance
Kristjansson 2010	Norway	182	80	57	Colorectal	Mixed	Surgery	LF	9.5	45.6	45.0	Mortality Complications
Liuu 2020	France	1092	82 ± 5	47	Various	Mixed	Various	LF	14	50	36	Mortality Unplanned admission
Lycke 2019	Belgium	944	80 (70–99)	48	Various	Mixed	Various	SF	73		27	Mortality
Martucci 2016	Brazil	136	73 ± 7	48	Various	Mixed	n.r.	SF	29.4	41.2	29.4	Mortality
Mazzuca 2019	Italy	ProLYOtin: 22	ProLYOtin: 68 (34–83)	ProLYOtin: 32	Colorectal	Mixed	Chemo	LF	ProLYOtin: 18	ProLYOtin: 50	ProLYOtin: 32	Toxicity
Mazzuca 2019	Italy	Placebo: 25	Placebo: 67 (49–85)	Placebo: 44	Colorectal	Mixed	Chemo	LF	Placebo: 16	Placebo: 36	Placebo: 48	Toxicity
Michaan 2020	Korea	120	76 ± 5	100	Gynaecologic	Mixed	Various	LF	20.4 ± 4.6^g			Mortality
Molga 2020	Australia	98	77 (66–95)	37	Hematological	Mixed	Various	LF	27		73	Mortality Treatment maintenance
Naito 2016	Japan	93	77 (65–90)^f	54	Non-Hodgkin Lymphoma	Mixed	Various	LF	40.9	59.1		Mortality
Osborne 2017	UK	178	74 (70–84)	0	Prostate	Mixed	Various	SF	0.0	6.7	82.6	Toxicity
Park 2015	Korea	70	74 (65–92)	46	Lymphomas	Mixed	Chemo	SF	35.7	37.1	27.1	Mortality Treatment maintenance
Quinten 2019	Belgium	741	81 (70–89)	43	Various	Mixed	Surgery	SF	74.4		25.6	Quality of Life
Quinten 2019	Belgium	683	77 (70–94)	47	Various	Mixed	Chemo	SF	81.4		18.6	Quality of Life
Retornaz 2020	France	97	79 (75–83)^l	51	Colorectal	Advanced	Chemo	SF	61.9		38.1	Mortality Toxicity
Samuelsson 2019	Sweden	49	81 (77–85)^l	53	Colorectal	Mixed	Surgery	SF	38.8		61.2	Complications Length of hospital stay
Scholtz 2018	Germany	517	71 (68–74)^l	32	Various	Mixed	Surgery	LF	2.3	23.8	73.9	Complications
Schütte 2015	Germany	51	66 ± 10	14	Hepatocellular	Mixed	n.r.	LF	0.0	17.3	62.7	Mortality
Shin 2012	Korea	64	71 (65–80)	25	Various	Mixed	Chemo	LF	21.9	59.4	18.7	Toxicity
Shiroyama 2017	Japan	30	76 (70–83)	13	Lung	Advanced	Chemo	SF	0.0^m	66.7	33.3	Toxicity
Soubeyran 2012	France	348	77 (70–99)	41	Various	Mixed	Chemo	LF	64.9		35.1	Mortality
Stauder 2020	Austria	147	78 (67–98)	46	Hematological	Mixed	Various	LF	15	43	42	Mortality
van Deudekom 2019	NL	102	79 (72–85)^l	30	Head & Neck	Mixed	Various	SF	39.2		61.8	Mortality
van der Vlies 2019	NL	99	77 (69–85)^l	37	Various	Advanced	Chemo	LF	85.0		15.0	Treatment maintenance Toxicity
Vande Walle 2014	Belgium	937	76 (70–95)	64	Various	Mixed	n.r.	SF	18.7	45.0	36.6	Falls
Vlachostergios 2013	Greece	103	67 (32–84)	10	Lung	Advanced	Systemic	LF	30.1	39.8	30.1	Mortality PFS

Legend: ^aNumber of included patients; ^bmean ± standard deviation (SD) or median (range); ^cpercentages may not add up to 100 due to rounding or missing values; ^dstepwise process – patients were classified as WN when SF > 12 or LF 24–30; ^estudies that were categorized to ‘mortality’ reported results on mortality or (poor) overall survival; ^fmean (range); ^gMNA-LF-score: X ± Y: mean ± SD or X (Y-Z) median (range: 0–30); ^h”Based on literature and the distribution of the mean values in the current study population“ [23]; ⁱtotal: 518; ^jmedian (SD); ^k87.8 ≥ 70 years; ^linterquartile-range (IQR); ^mMN patients were excluded from study participation
MNA Mini Nutritional Assessment; SF short-form; LF long-form; MN malnourished; AR at risk for malnutrition; WN well-nourished; n.a not applicable; n.r. not reported; PFS progression-free survival; TTP time to progression; NL The Netherlands; UK United Kingdom; US United States of America

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us